First-trimester exposure to amoxycillin/clavulanic acid: a prospective, controlled study

被引:27
作者
Berkovitch, M [1 ]
Diav-Citrin, O
Greenberg, R
Cohen, M
Bulkowstein, M
Shechtman, S
Bortnik, O
Arnon, J
Ornoy, A
机构
[1] Tel Aviv Univ, Sackler Sch Med, Assaf Harofeh Med Ctr, Clin Pharm & Toxicol Unit,Drug Consultat Ctr, IL-70300 Zerifin, Israel
[2] Israeli Teratogen Informat Serv, Minist Hlth, Jerusalem, Israel
[3] Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91010 Jerusalem, Israel
关键词
amoxycillin; malformations; moxycillin/clavulanic acid; pregnancy; teratogenicity;
D O I
10.1111/j.1365-2125.2004.02138.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims The number of published studies on the use of amoxycillin/clavulanic acid during pregnancy is small and so is the number of pregnancies investigated in those studies. In this study we wished to investigate prospectively the safety of intrauterine exposure to amoxycillin/clavulanic acid in a relatively large cohort of women. Methods Women treated (n = 191) with amoxycillin/clavulanic acid during the first trimester of pregnancy were recruited from two teratogen information centres in Israel. Exposed women were matched for age, smoking habits and alcohol consumption with 191 controls exposed to amoxycillin only for similar medical indications. Results Maternal age, birth weight, gestational age at delivery, rates of live births and abortions were comparable between the two groups. Rates of major malformations in the amoxycillin/clavulanic acid group (3/158, 1.9%) did not differ significantly from controls (5/163, 3%) (P = 0.49, relative risk = 0.62, 95% confidence interval 0.15, 2.55), and were within the expected baseline risk for the general population. Conclusion These data suggest that exposure to amoxycillin/clavulanic acid during pregnancy is unlikely to be associated with an increased risk of malformations.
引用
收藏
页码:298 / 302
页数:5
相关论文
共 22 条
[1]  
BALDWIN JA, 1983, CHEMOTERAPY, V31, P238
[2]   Augmentin treatment during pregnancy and the prevalence of congenital abnormalities - A population-based case-control teratologic study [J].
Czeizel, AE ;
Rockenbauer, M ;
Sorensen, HT ;
Olsen, J .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2001, 97 (02) :188-192
[3]   Therapeutic drug use during pregnancy:: A comparison in four European countries [J].
De Vigan, C ;
De Walle, HEK ;
Cordier, S ;
Goujard, J ;
Knill-Jones, R ;
Aymé, S ;
Calzolari, E ;
Bianchi, F .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1999, 52 (10) :977-982
[4]  
Fleiss J. L., 1981, Statistical Methods for Rates and Proportions, V2nd
[5]   TRANSFER OF TIMENTIN (TICARCILLIN AND CLAVULANIC ACID) ACROSS THE INVITRO PERFUSED HUMAN PLACENTA - COMPARISON WITH OTHER AGENTS [J].
FORTUNATO, SJ ;
BAWDON, RE ;
SWAN, KF ;
BRYANT, EC ;
SOBHI, S .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 167 (06) :1595-1599
[6]   A practical look at the clinical usefulness of the beta-lactam/beta-lactamase inhibitor combinations [J].
Hart, SM ;
Bailey, EM .
ANNALS OF PHARMACOTHERAPY, 1996, 30 (10) :1130-1140
[7]  
Heinonen O, 1977, BIRTH DEFECTS DRUGS
[8]  
HIRAKAWA T, 1983, CHEMOTHERAPY, V31, P263
[9]   The teratogenicity of anticonvulsant drugs. [J].
Holmes, LB ;
Harvey, EA ;
Coull, BA ;
Huntington, KB ;
Khoshbin, S ;
Hayes, AM ;
Ryan, LM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (15) :1132-1138
[10]   INVITRO SYNERGISTIC PROPERTIES OF CLAVULANIC ACID, WITH AMPICILLIN, AMOXYCILLIN AND TICARCILLIN [J].
HUNTER, PA ;
COLEMAN, K ;
FISHER, J ;
TAYLOR, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1980, 6 (04) :455-470